NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.

Clinical Parkinsonism & Related Disorders is a prominent open-access journal published by Elsevier, focused on advancing the understanding and treatment of Parkinson's disease and related neurological conditions. Since its inception in 2019, this journal has aimed to provide a platform for high-quality research, review articles, and clinical studies dedicated to elucidating the complexities of Parkinsonism and its comorbidities. With an E-ISSN of 2590-1125, it has swiftly established its role in the field of clinical neurology, currently ranked in the Q3 quartile for clinical neurology and Q4 for cellular and molecular neuroscience. While its Scopus rankings reflect a competitive landscape, occupying the 241st position in clinical neurology and the 83rd in neuroscience, the journal remains committed to fostering scholarly dialogue and supporting innovative research. Researchers, clinicians, and students will find valuable insights within its pages, contributing to ongoing discourse and the pursuit of effective therapeutic strategies. Access to all articles has been made available since 2019, emphasizing the journal's mission to disseminate knowledge widely and enhance accessibility in the scientific community.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

MOVEMENT DISORDERS, published by Wiley, stands as a premier outlet for cutting-edge research in the field of neurology, particularly focusing on the various aspects of movement disorders. With both its ISSN (0885-3185) and E-ISSN (1531-8257) identifiers, this journal is at the forefront of neurological research, holding a remarkable impact factor and recognized in the top quartiles (Q1) of the disciplines of Neurology and Clinical Neurology as of 2023. The journal boasts an impressive Scopus ranking, placing it in the top 8 out of 192 for Neuroscience-Neprology and 19 out of 400 for Medicine-Clinical Neurology, reflecting its high relevance and influence in the field. Released quarterly since its inception in 1986 and continuing through 2024, MOVEMENT DISORDERS publishes a mix of original research articles, reviews, and case reports that catalyze innovation and foster collaboration among researchers, healthcare professionals, and students dedicated to understanding and treating movement disorders. As a non-open access journal, it nevertheless offers valuable insights that are essential for the advancement of knowledge in neurology, making it a critical resource for anyone invested in this challenging and evolving field.

CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.

EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.

The Journal of Huntington's Disease is a premier academic publication dedicated to advancing the understanding of Huntington's disease and related neurodegenerative disorders. Published by IOS PRESS, this journal has established itself as a vital resource for the scientific community, with an impressive impact factor reflecting its rigorous standards and influential research contributions. With a converged publication period from 2012 to 2024, the journal holds esteemed rankings in the 2023 Q2 category for Cellular and Molecular Neuroscience and Q1 for Neurology (clinical) on Scopus, highlighting its relevance and authority within these critical fields. Researchers, professionals, and students will find a wealth of peer-reviewed articles that examine the molecular mechanisms, clinical manifestations, and therapeutic strategies related to Huntington’s disease. Although not an open-access journal, it provides various access options to ensure that critical research reaches its intended audience. As an essential platform for disseminating groundbreaking findings in neurology and neuroscience, the Journal of Huntington's Disease plays a crucial role in shaping the future of research and treatment strategies related to this devastating condition.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

PARKINSONISM & RELATED DISORDERS, published by Elsevier Science Ltd, is a prominent peer-reviewed journal dedicated to advancing the understanding of Parkinson's disease and related neurodegenerative disorders. With an impact factor placing it in the Q2 category across multiple fields including Geriatrics and Gerontology and Neurology for 2023, this journal serves as a crucial platform for researchers, healthcare professionals, and students alike. Covering an array of topics from clinical trials to innovative therapeutic strategies, it aims to disseminate valuable insights that can improve patient care and outcomes. While it remains a subscription-based journal, its relevance is underscored by its consistent rankings in Scopus, where it ranks 105th in Clinical Neurology and 35th in Geriatrics and Gerontology. Authored by top scholars in the field, PARKINSONISM & RELATED DISORDERS continues to contribute significantly to the body of knowledge surrounding these debilitating conditions, facilitating the exchange of cutting-edge research and fostering collaboration within the scientific community.

AIMS Neuroscience is an esteemed open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to advancing the field of neuroscience since its inception in 2014. With a robust ISSN of 2373-8006 and an E-ISSN of 2373-7972, this journal aims to provide a platform for innovative research and scholarly discourse that spans the diverse and dynamic landscape of the neuroscience discipline. As of 2023, it holds a respectable Q3 category ranking in the miscellaneous neuroscience field and ranks #65 out of 113 in general neuroscience according to Scopus, positioning it in the 42nd percentile for impact. AIMS Neuroscience encompasses a broad scope of topics, from neurobiology and cognitive neuroscience to computational models and neuroengineering, making it a vital resource for researchers, professionals, and students alike. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and knowledge sharing within the global neuroscience community.